nodes	percent_of_prediction	percent_of_DWPC	metapath
Midazolam—SLC22A1—Progesterone—uterine cancer	0.143	0.21	CbGbCtD
Midazolam—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.0896	0.132	CbGbCtD
Midazolam—CYP3A7—Progesterone—uterine cancer	0.0896	0.132	CbGbCtD
Midazolam—CYP3A5—Progesterone—uterine cancer	0.0672	0.0987	CbGbCtD
Midazolam—ABCB1—Progesterone—uterine cancer	0.0438	0.0642	CbGbCtD
Midazolam—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0396	0.0581	CbGbCtD
Midazolam—CYP2E1—Etoposide—uterine cancer	0.0387	0.0568	CbGbCtD
Midazolam—ABCB1—Dactinomycin—uterine cancer	0.0347	0.0509	CbGbCtD
Midazolam—CYP3A5—Etoposide—uterine cancer	0.0301	0.0442	CbGbCtD
Midazolam—CYP3A4—Progesterone—uterine cancer	0.0262	0.0385	CbGbCtD
Midazolam—CYP2B6—Doxorubicin—uterine cancer	0.0261	0.0382	CbGbCtD
Midazolam—ABCB1—Etoposide—uterine cancer	0.0196	0.0288	CbGbCtD
Midazolam—ABCB1—Doxorubicin—uterine cancer	0.0134	0.0196	CbGbCtD
Midazolam—CYP3A4—Etoposide—uterine cancer	0.0117	0.0172	CbGbCtD
Midazolam—CYP3A4—Doxorubicin—uterine cancer	0.008	0.0117	CbGbCtD
Midazolam—CYP4B1—uterine cervix—uterine cancer	0.00297	0.0491	CbGeAlD
Midazolam—CYP4B1—decidua—uterine cancer	0.00283	0.0468	CbGeAlD
Midazolam—UGT1A4—renal system—uterine cancer	0.00282	0.0466	CbGeAlD
Midazolam—CYP4B1—endometrium—uterine cancer	0.00269	0.0444	CbGeAlD
Midazolam—CYP4B1—mammalian vulva—uterine cancer	0.0026	0.043	CbGeAlD
Midazolam—CYP4B1—uterus—uterine cancer	0.00248	0.0409	CbGeAlD
Midazolam—CYP4B1—female reproductive system—uterine cancer	0.00223	0.0368	CbGeAlD
Midazolam—CYP4B1—female gonad—uterine cancer	0.00203	0.0335	CbGeAlD
Midazolam—CYP4B1—vagina—uterine cancer	0.00201	0.0333	CbGeAlD
Midazolam—GABRP—uterine cervix—uterine cancer	0.00167	0.0277	CbGeAlD
Midazolam—GABRE—myometrium—uterine cancer	0.00164	0.0271	CbGeAlD
Midazolam—GABRP—decidua—uterine cancer	0.00159	0.0264	CbGeAlD
Midazolam—GABRP—endometrium—uterine cancer	0.00151	0.025	CbGeAlD
Midazolam—GABRA4—mammalian vulva—uterine cancer	0.00147	0.0244	CbGeAlD
Midazolam—GABRP—uterus—uterine cancer	0.00139	0.0231	CbGeAlD
Midazolam—CYP4B1—lymph node—uterine cancer	0.0013	0.0215	CbGeAlD
Midazolam—GABRE—uterine cervix—uterine cancer	0.00128	0.0211	CbGeAlD
Midazolam—GABRB1—vagina—uterine cancer	0.00127	0.0209	CbGeAlD
Midazolam—GABRP—female reproductive system—uterine cancer	0.00125	0.0207	CbGeAlD
Midazolam—GABRE—decidua—uterine cancer	0.00122	0.0201	CbGeAlD
Midazolam—GABRE—endometrium—uterine cancer	0.00116	0.0191	CbGeAlD
Midazolam—SLC22A1—renal system—uterine cancer	0.00114	0.0188	CbGeAlD
Midazolam—GABRP—vagina—uterine cancer	0.00113	0.0187	CbGeAlD
Midazolam—GABRE—mammalian vulva—uterine cancer	0.00112	0.0185	CbGeAlD
Midazolam—GABRR2—lymph node—uterine cancer	0.00105	0.0173	CbGeAlD
Midazolam—GABRE—female reproductive system—uterine cancer	0.000957	0.0158	CbGeAlD
Midazolam—GABRA2—vagina—uterine cancer	0.000873	0.0144	CbGeAlD
Midazolam—GABRE—female gonad—uterine cancer	0.000871	0.0144	CbGeAlD
Midazolam—GABRE—vagina—uterine cancer	0.000865	0.0143	CbGeAlD
Midazolam—SLC22A1—vagina—uterine cancer	0.000824	0.0136	CbGeAlD
Midazolam—GABRB3—female reproductive system—uterine cancer	0.000811	0.0134	CbGeAlD
Midazolam—CYP3A5—uterine cervix—uterine cancer	0.000738	0.0122	CbGeAlD
Midazolam—Nystagmus—Doxorubicin—uterine cancer	0.00071	0.00307	CcSEcCtD
Midazolam—Tremor—Medroxyprogesterone Acetate—uterine cancer	0.000709	0.00307	CcSEcCtD
Midazolam—Anxiety—Progesterone—uterine cancer	0.000709	0.00307	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.000706	0.00306	CcSEcCtD
Midazolam—Feeling hot—Epirubicin—uterine cancer	0.000698	0.00302	CcSEcCtD
Midazolam—Agitation—Medroxyprogesterone Acetate—uterine cancer	0.000696	0.00301	CcSEcCtD
Midazolam—Dry mouth—Progesterone—uterine cancer	0.000696	0.00301	CcSEcCtD
Midazolam—CYP3A5—renal system—uterine cancer	0.000691	0.0114	CbGeAlD
Midazolam—Confusional state—Progesterone—uterine cancer	0.000688	0.00297	CcSEcCtD
Midazolam—CYP2B6—renal system—uterine cancer	0.000687	0.0114	CbGeAlD
Midazolam—Anaphylactic shock—Progesterone—uterine cancer	0.000682	0.00295	CcSEcCtD
Midazolam—Vertigo—Medroxyprogesterone Acetate—uterine cancer	0.00068	0.00294	CcSEcCtD
Midazolam—Syncope—Medroxyprogesterone Acetate—uterine cancer	0.000679	0.00294	CcSEcCtD
Midazolam—Cardiac arrest—Etoposide—uterine cancer	0.000675	0.00292	CcSEcCtD
Midazolam—Injection site pain—Epirubicin—uterine cancer	0.000671	0.0029	CcSEcCtD
Midazolam—Shock—Progesterone—uterine cancer	0.000671	0.0029	CcSEcCtD
Midazolam—Nervous system disorder—Progesterone—uterine cancer	0.000669	0.00289	CcSEcCtD
Midazolam—Dysphonia—Epirubicin—uterine cancer	0.000666	0.00288	CcSEcCtD
Midazolam—Tachycardia—Progesterone—uterine cancer	0.000666	0.00288	CcSEcCtD
Midazolam—Skin disorder—Progesterone—uterine cancer	0.000662	0.00287	CcSEcCtD
Midazolam—Feeling hot—Doxorubicin—uterine cancer	0.000646	0.0028	CcSEcCtD
Midazolam—CYP2E1—renal system—uterine cancer	0.000644	0.0107	CbGeAlD
Midazolam—Anxiety—Medroxyprogesterone Acetate—uterine cancer	0.000642	0.00278	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.00064	0.00277	CcSEcCtD
Midazolam—Delirium—Epirubicin—uterine cancer	0.000637	0.00276	CcSEcCtD
Midazolam—Hypotension—Progesterone—uterine cancer	0.000637	0.00276	CcSEcCtD
Midazolam—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.00063	0.00273	CcSEcCtD
Midazolam—Confusional state—Medroxyprogesterone Acetate—uterine cancer	0.000623	0.0027	CcSEcCtD
Midazolam—Injection site pain—Doxorubicin—uterine cancer	0.000621	0.00269	CcSEcCtD
Midazolam—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.000618	0.00267	CcSEcCtD
Midazolam—Dysphonia—Doxorubicin—uterine cancer	0.000616	0.00267	CcSEcCtD
Midazolam—Paraesthesia—Progesterone—uterine cancer	0.000612	0.00265	CcSEcCtD
Midazolam—Chills—Dactinomycin—uterine cancer	0.000609	0.00263	CcSEcCtD
Midazolam—Dyspnoea—Progesterone—uterine cancer	0.000608	0.00263	CcSEcCtD
Midazolam—Shock—Medroxyprogesterone Acetate—uterine cancer	0.000608	0.00263	CcSEcCtD
Midazolam—Ventricular extrasystoles—Epirubicin—uterine cancer	0.000607	0.00262	CcSEcCtD
Midazolam—Somnolence—Progesterone—uterine cancer	0.000606	0.00262	CcSEcCtD
Midazolam—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000606	0.00262	CcSEcCtD
Midazolam—Bronchospasm—Etoposide—uterine cancer	0.000603	0.00261	CcSEcCtD
Midazolam—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.000603	0.00261	CcSEcCtD
Midazolam—Dyspepsia—Progesterone—uterine cancer	0.0006	0.0026	CcSEcCtD
Midazolam—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.0006	0.0026	CcSEcCtD
Midazolam—Erythema—Dactinomycin—uterine cancer	0.000591	0.00255	CcSEcCtD
Midazolam—Delirium—Doxorubicin—uterine cancer	0.00059	0.00255	CcSEcCtD
Midazolam—Gastrointestinal disorder—Progesterone—uterine cancer	0.000589	0.00255	CcSEcCtD
Midazolam—Fatigue—Progesterone—uterine cancer	0.000588	0.00254	CcSEcCtD
Midazolam—Dyskinesia—Epirubicin—uterine cancer	0.000583	0.00252	CcSEcCtD
Midazolam—Pain—Progesterone—uterine cancer	0.000583	0.00252	CcSEcCtD
Midazolam—Constipation—Progesterone—uterine cancer	0.000583	0.00252	CcSEcCtD
Midazolam—Dysarthria—Epirubicin—uterine cancer	0.000579	0.00251	CcSEcCtD
Midazolam—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.000577	0.0025	CcSEcCtD
Midazolam—GABRA2—lymph node—uterine cancer	0.000565	0.00933	CbGeAlD
Midazolam—Feeling abnormal—Progesterone—uterine cancer	0.000562	0.00243	CcSEcCtD
Midazolam—Ventricular extrasystoles—Doxorubicin—uterine cancer	0.000561	0.00243	CcSEcCtD
Midazolam—GABRE—lymph node—uterine cancer	0.00056	0.00925	CbGeAlD
Midazolam—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.000555	0.0024	CcSEcCtD
Midazolam—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000551	0.00238	CcSEcCtD
Midazolam—CYP2B6—female reproductive system—uterine cancer	0.00055	0.00909	CbGeAlD
Midazolam—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.000549	0.00238	CcSEcCtD
Midazolam—Ventricular tachycardia—Epirubicin—uterine cancer	0.000548	0.00237	CcSEcCtD
Midazolam—Hiccups—Epirubicin—uterine cancer	0.000548	0.00237	CcSEcCtD
Midazolam—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000544	0.00235	CcSEcCtD
Midazolam—Urticaria—Progesterone—uterine cancer	0.000542	0.00234	CcSEcCtD
Midazolam—Dyskinesia—Doxorubicin—uterine cancer	0.00054	0.00233	CcSEcCtD
Midazolam—Dysarthria—Doxorubicin—uterine cancer	0.000536	0.00232	CcSEcCtD
Midazolam—Neuropathy peripheral—Etoposide—uterine cancer	0.000536	0.00232	CcSEcCtD
Midazolam—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000533	0.00231	CcSEcCtD
Midazolam—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000533	0.0023	CcSEcCtD
Midazolam—Salivary hypersecretion—Epirubicin—uterine cancer	0.000532	0.0023	CcSEcCtD
Midazolam—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000528	0.00229	CcSEcCtD
Midazolam—Skin exfoliation—Epirubicin—uterine cancer	0.000523	0.00226	CcSEcCtD
Midazolam—CYP3A4—renal system—uterine cancer	0.000518	0.00857	CbGeAlD
Midazolam—CYP2E1—female reproductive system—uterine cancer	0.000516	0.00853	CbGeAlD
Midazolam—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.000509	0.0022	CcSEcCtD
Midazolam—Ventricular tachycardia—Doxorubicin—uterine cancer	0.000507	0.00219	CcSEcCtD
Midazolam—Hiccups—Doxorubicin—uterine cancer	0.000507	0.00219	CcSEcCtD
Midazolam—ABCB1—myometrium—uterine cancer	0.000504	0.00833	CbGeAlD
Midazolam—CYP3A5—female gonad—uterine cancer	0.000503	0.00832	CbGeAlD
Midazolam—Hypersensitivity—Progesterone—uterine cancer	0.000502	0.00217	CcSEcCtD
Midazolam—CYP3A5—vagina—uterine cancer	0.0005	0.00827	CbGeAlD
Midazolam—CYP2B6—vagina—uterine cancer	0.000497	0.00822	CbGeAlD
Midazolam—Salivary hypersecretion—Doxorubicin—uterine cancer	0.000492	0.00213	CcSEcCtD
Midazolam—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000491	0.00212	CcSEcCtD
Midazolam—Asthenia—Progesterone—uterine cancer	0.000489	0.00212	CcSEcCtD
Midazolam—Skin exfoliation—Doxorubicin—uterine cancer	0.000484	0.00209	CcSEcCtD
Midazolam—Pruritus—Progesterone—uterine cancer	0.000482	0.00209	CcSEcCtD
Midazolam—Phlebitis—Epirubicin—uterine cancer	0.000462	0.002	CcSEcCtD
Midazolam—Thrombophlebitis—Epirubicin—uterine cancer	0.00046	0.00199	CcSEcCtD
Midazolam—Eye disorder—Etoposide—uterine cancer	0.000459	0.00198	CcSEcCtD
Midazolam—Cardiac disorder—Etoposide—uterine cancer	0.000456	0.00197	CcSEcCtD
Midazolam—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000455	0.00197	CcSEcCtD
Midazolam—Dizziness—Progesterone—uterine cancer	0.000451	0.00195	CcSEcCtD
Midazolam—Immune system disorder—Etoposide—uterine cancer	0.000443	0.00192	CcSEcCtD
Midazolam—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000443	0.00192	CcSEcCtD
Midazolam—Mediastinal disorder—Etoposide—uterine cancer	0.000443	0.00191	CcSEcCtD
Midazolam—Chills—Etoposide—uterine cancer	0.000441	0.00191	CcSEcCtD
Midazolam—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000437	0.00189	CcSEcCtD
Midazolam—Vomiting—Progesterone—uterine cancer	0.000434	0.00188	CcSEcCtD
Midazolam—Rash—Progesterone—uterine cancer	0.00043	0.00186	CcSEcCtD
Midazolam—Dermatitis—Progesterone—uterine cancer	0.00043	0.00186	CcSEcCtD
Midazolam—Phlebitis—Doxorubicin—uterine cancer	0.000427	0.00185	CcSEcCtD
Midazolam—Headache—Progesterone—uterine cancer	0.000427	0.00185	CcSEcCtD
Midazolam—Thrombophlebitis—Doxorubicin—uterine cancer	0.000425	0.00184	CcSEcCtD
Midazolam—Fatigue—Dactinomycin—uterine cancer	0.000416	0.0018	CcSEcCtD
Midazolam—CYP3A4—female reproductive system—uterine cancer	0.000415	0.00686	CbGeAlD
Midazolam—Pain—Dactinomycin—uterine cancer	0.000412	0.00178	CcSEcCtD
Midazolam—Anaphylactoid reaction—Epirubicin—uterine cancer	0.000411	0.00178	CcSEcCtD
Midazolam—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000409	0.00177	CcSEcCtD
Midazolam—Cardiac failure—Epirubicin—uterine cancer	0.000408	0.00176	CcSEcCtD
Midazolam—Lethargy—Epirubicin—uterine cancer	0.000406	0.00176	CcSEcCtD
Midazolam—Nausea—Progesterone—uterine cancer	0.000405	0.00175	CcSEcCtD
Midazolam—Osteoarthritis—Epirubicin—uterine cancer	0.000398	0.00172	CcSEcCtD
Midazolam—Diplopia—Epirubicin—uterine cancer	0.000398	0.00172	CcSEcCtD
Midazolam—Feeling abnormal—Dactinomycin—uterine cancer	0.000397	0.00172	CcSEcCtD
Midazolam—ABCB1—epithelium—uterine cancer	0.000396	0.00654	CbGeAlD
Midazolam—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000393	0.0017	CcSEcCtD
Midazolam—ABCB1—uterine cervix—uterine cancer	0.000392	0.00649	CbGeAlD
Midazolam—Affect lability—Epirubicin—uterine cancer	0.000392	0.00169	CcSEcCtD
Midazolam—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00039	0.00169	CcSEcCtD
Midazolam—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000389	0.00168	CcSEcCtD
Midazolam—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000387	0.00167	CcSEcCtD
Midazolam—Vertigo—Etoposide—uterine cancer	0.000384	0.00166	CcSEcCtD
Midazolam—Anaphylactoid reaction—Doxorubicin—uterine cancer	0.00038	0.00165	CcSEcCtD
Midazolam—Cardiac arrest—Epirubicin—uterine cancer	0.000378	0.00164	CcSEcCtD
Midazolam—Cardiac failure—Doxorubicin—uterine cancer	0.000377	0.00163	CcSEcCtD
Midazolam—Mood swings—Epirubicin—uterine cancer	0.000377	0.00163	CcSEcCtD
Midazolam—Lethargy—Doxorubicin—uterine cancer	0.000376	0.00163	CcSEcCtD
Midazolam—Ataxia—Epirubicin—uterine cancer	0.000374	0.00162	CcSEcCtD
Midazolam—ABCB1—decidua—uterine cancer	0.000374	0.00618	CbGeAlD
Midazolam—Cough—Etoposide—uterine cancer	0.000373	0.00161	CcSEcCtD
Midazolam—Osteoarthritis—Doxorubicin—uterine cancer	0.000368	0.00159	CcSEcCtD
Midazolam—Diplopia—Doxorubicin—uterine cancer	0.000368	0.00159	CcSEcCtD
Midazolam—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000367	0.00159	CcSEcCtD
Midazolam—ABCB1—renal system—uterine cancer	0.000367	0.00607	CbGeAlD
Midazolam—Affect lability—Doxorubicin—uterine cancer	0.000362	0.00157	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000361	0.00156	CcSEcCtD
Midazolam—Nasopharyngitis—Epirubicin—uterine cancer	0.000356	0.00154	CcSEcCtD
Midazolam—Hypersensitivity—Dactinomycin—uterine cancer	0.000355	0.00154	CcSEcCtD
Midazolam—ABCB1—endometrium—uterine cancer	0.000355	0.00587	CbGeAlD
Midazolam—Confusional state—Etoposide—uterine cancer	0.000352	0.00152	CcSEcCtD
Midazolam—Muscular weakness—Epirubicin—uterine cancer	0.000351	0.00152	CcSEcCtD
Midazolam—Cardiac arrest—Doxorubicin—uterine cancer	0.00035	0.00151	CcSEcCtD
Midazolam—Anaphylactic shock—Etoposide—uterine cancer	0.000349	0.00151	CcSEcCtD
Midazolam—Mood swings—Doxorubicin—uterine cancer	0.000349	0.00151	CcSEcCtD
Midazolam—Ataxia—Doxorubicin—uterine cancer	0.000346	0.0015	CcSEcCtD
Midazolam—Asthenia—Dactinomycin—uterine cancer	0.000346	0.0015	CcSEcCtD
Midazolam—ABCB1—mammalian vulva—uterine cancer	0.000343	0.00567	CbGeAlD
Midazolam—Tachycardia—Etoposide—uterine cancer	0.00034	0.00147	CcSEcCtD
Midazolam—Skin disorder—Etoposide—uterine cancer	0.000339	0.00147	CcSEcCtD
Midazolam—Nasopharyngitis—Doxorubicin—uterine cancer	0.000329	0.00142	CcSEcCtD
Midazolam—ABCB1—uterus—uterine cancer	0.000327	0.00541	CbGeAlD
Midazolam—Hypotension—Etoposide—uterine cancer	0.000326	0.00141	CcSEcCtD
Midazolam—Muscular weakness—Doxorubicin—uterine cancer	0.000325	0.0014	CcSEcCtD
Midazolam—Paraesthesia—Etoposide—uterine cancer	0.000313	0.00136	CcSEcCtD
Midazolam—Dyspnoea—Etoposide—uterine cancer	0.000311	0.00135	CcSEcCtD
Midazolam—Somnolence—Etoposide—uterine cancer	0.00031	0.00134	CcSEcCtD
Midazolam—Drowsiness—Epirubicin—uterine cancer	0.000307	0.00133	CcSEcCtD
Midazolam—Vomiting—Dactinomycin—uterine cancer	0.000306	0.00133	CcSEcCtD
Midazolam—Rash—Dactinomycin—uterine cancer	0.000304	0.00131	CcSEcCtD
Midazolam—Gastrointestinal disorder—Etoposide—uterine cancer	0.000301	0.0013	CcSEcCtD
Midazolam—Fatigue—Etoposide—uterine cancer	0.000301	0.0013	CcSEcCtD
Midazolam—Neuropathy peripheral—Epirubicin—uterine cancer	0.000301	0.0013	CcSEcCtD
Midazolam—Constipation—Etoposide—uterine cancer	0.000298	0.00129	CcSEcCtD
Midazolam—Pain—Etoposide—uterine cancer	0.000298	0.00129	CcSEcCtD
Midazolam—ABCB1—female reproductive system—uterine cancer	0.000294	0.00486	CbGeAlD
Midazolam—Feeling abnormal—Etoposide—uterine cancer	0.000287	0.00124	CcSEcCtD
Midazolam—Nausea—Dactinomycin—uterine cancer	0.000286	0.00124	CcSEcCtD
Midazolam—Drowsiness—Doxorubicin—uterine cancer	0.000284	0.00123	CcSEcCtD
Midazolam—Bradycardia—Epirubicin—uterine cancer	0.00028	0.00121	CcSEcCtD
Midazolam—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000278	0.0012	CcSEcCtD
Midazolam—Urticaria—Etoposide—uterine cancer	0.000277	0.0012	CcSEcCtD
Midazolam—Connective tissue disorder—Epirubicin—uterine cancer	0.00027	0.00117	CcSEcCtD
Midazolam—ABCB1—female gonad—uterine cancer	0.000267	0.00442	CbGeAlD
Midazolam—ABCB1—vagina—uterine cancer	0.000266	0.00439	CbGeAlD
Midazolam—Visual impairment—Epirubicin—uterine cancer	0.000265	0.00115	CcSEcCtD
Midazolam—Bradycardia—Doxorubicin—uterine cancer	0.000259	0.00112	CcSEcCtD
Midazolam—Eye disorder—Epirubicin—uterine cancer	0.000257	0.00111	CcSEcCtD
Midazolam—Hypersensitivity—Etoposide—uterine cancer	0.000257	0.00111	CcSEcCtD
Midazolam—Cardiac disorder—Epirubicin—uterine cancer	0.000255	0.0011	CcSEcCtD
Midazolam—Asthenia—Etoposide—uterine cancer	0.00025	0.00108	CcSEcCtD
Midazolam—Connective tissue disorder—Doxorubicin—uterine cancer	0.00025	0.00108	CcSEcCtD
Midazolam—Immune system disorder—Epirubicin—uterine cancer	0.000249	0.00108	CcSEcCtD
Midazolam—Mediastinal disorder—Epirubicin—uterine cancer	0.000248	0.00107	CcSEcCtD
Midazolam—Chills—Epirubicin—uterine cancer	0.000247	0.00107	CcSEcCtD
Midazolam—Pruritus—Etoposide—uterine cancer	0.000247	0.00107	CcSEcCtD
Midazolam—Visual impairment—Doxorubicin—uterine cancer	0.000245	0.00106	CcSEcCtD
Midazolam—Mental disorder—Epirubicin—uterine cancer	0.000241	0.00104	CcSEcCtD
Midazolam—Erythema—Epirubicin—uterine cancer	0.00024	0.00104	CcSEcCtD
Midazolam—Eye disorder—Doxorubicin—uterine cancer	0.000238	0.00103	CcSEcCtD
Midazolam—Cardiac disorder—Doxorubicin—uterine cancer	0.000236	0.00102	CcSEcCtD
Midazolam—Tension—Epirubicin—uterine cancer	0.000235	0.00102	CcSEcCtD
Midazolam—Nervousness—Epirubicin—uterine cancer	0.000233	0.00101	CcSEcCtD
Midazolam—Dizziness—Etoposide—uterine cancer	0.000231	0.000998	CcSEcCtD
Midazolam—Immune system disorder—Doxorubicin—uterine cancer	0.00023	0.000995	CcSEcCtD
Midazolam—Mediastinal disorder—Doxorubicin—uterine cancer	0.00023	0.000993	CcSEcCtD
Midazolam—Chills—Doxorubicin—uterine cancer	0.000229	0.000988	CcSEcCtD
Midazolam—Vision blurred—Epirubicin—uterine cancer	0.000226	0.000977	CcSEcCtD
Midazolam—Mental disorder—Doxorubicin—uterine cancer	0.000223	0.000965	CcSEcCtD
Midazolam—Vomiting—Etoposide—uterine cancer	0.000222	0.000959	CcSEcCtD
Midazolam—Erythema—Doxorubicin—uterine cancer	0.000222	0.000959	CcSEcCtD
Midazolam—Agitation—Epirubicin—uterine cancer	0.00022	0.000952	CcSEcCtD
Midazolam—Rash—Etoposide—uterine cancer	0.00022	0.000951	CcSEcCtD
Midazolam—Dermatitis—Etoposide—uterine cancer	0.00022	0.000951	CcSEcCtD
Midazolam—Headache—Etoposide—uterine cancer	0.000219	0.000945	CcSEcCtD
Midazolam—Tension—Doxorubicin—uterine cancer	0.000218	0.000941	CcSEcCtD
Midazolam—Nervousness—Doxorubicin—uterine cancer	0.000215	0.000931	CcSEcCtD
Midazolam—Vertigo—Epirubicin—uterine cancer	0.000215	0.000931	CcSEcCtD
Midazolam—Syncope—Epirubicin—uterine cancer	0.000215	0.000929	CcSEcCtD
Midazolam—Cough—Epirubicin—uterine cancer	0.000209	0.000904	CcSEcCtD
Midazolam—Vision blurred—Doxorubicin—uterine cancer	0.000209	0.000904	CcSEcCtD
Midazolam—Nausea—Etoposide—uterine cancer	0.000207	0.000896	CcSEcCtD
Midazolam—Agitation—Doxorubicin—uterine cancer	0.000204	0.000881	CcSEcCtD
Midazolam—Anxiety—Epirubicin—uterine cancer	0.000203	0.000879	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000203	0.000876	CcSEcCtD
Midazolam—Dry mouth—Epirubicin—uterine cancer	0.000199	0.000863	CcSEcCtD
Midazolam—Vertigo—Doxorubicin—uterine cancer	0.000199	0.000862	CcSEcCtD
Midazolam—Syncope—Doxorubicin—uterine cancer	0.000199	0.00086	CcSEcCtD
Midazolam—Confusional state—Epirubicin—uterine cancer	0.000197	0.000853	CcSEcCtD
Midazolam—Anaphylactic shock—Epirubicin—uterine cancer	0.000196	0.000846	CcSEcCtD
Midazolam—Cough—Doxorubicin—uterine cancer	0.000193	0.000837	CcSEcCtD
Midazolam—Shock—Epirubicin—uterine cancer	0.000192	0.000832	CcSEcCtD
Midazolam—Nervous system disorder—Epirubicin—uterine cancer	0.000192	0.00083	CcSEcCtD
Midazolam—Tachycardia—Epirubicin—uterine cancer	0.000191	0.000826	CcSEcCtD
Midazolam—Skin disorder—Epirubicin—uterine cancer	0.00019	0.000822	CcSEcCtD
Midazolam—Anxiety—Doxorubicin—uterine cancer	0.000188	0.000814	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000187	0.000811	CcSEcCtD
Midazolam—Dry mouth—Doxorubicin—uterine cancer	0.000185	0.000798	CcSEcCtD
Midazolam—Hypotension—Epirubicin—uterine cancer	0.000183	0.00079	CcSEcCtD
Midazolam—Confusional state—Doxorubicin—uterine cancer	0.000182	0.000789	CcSEcCtD
Midazolam—Anaphylactic shock—Doxorubicin—uterine cancer	0.000181	0.000783	CcSEcCtD
Midazolam—Shock—Doxorubicin—uterine cancer	0.000178	0.00077	CcSEcCtD
Midazolam—Nervous system disorder—Doxorubicin—uterine cancer	0.000177	0.000768	CcSEcCtD
Midazolam—Tachycardia—Doxorubicin—uterine cancer	0.000177	0.000764	CcSEcCtD
Midazolam—Skin disorder—Doxorubicin—uterine cancer	0.000176	0.00076	CcSEcCtD
Midazolam—Paraesthesia—Epirubicin—uterine cancer	0.000176	0.00076	CcSEcCtD
Midazolam—Dyspnoea—Epirubicin—uterine cancer	0.000174	0.000754	CcSEcCtD
Midazolam—Somnolence—Epirubicin—uterine cancer	0.000174	0.000752	CcSEcCtD
Midazolam—Dyspepsia—Epirubicin—uterine cancer	0.000172	0.000745	CcSEcCtD
Midazolam—ABCB1—lymph node—uterine cancer	0.000172	0.00284	CbGeAlD
Midazolam—Hypotension—Doxorubicin—uterine cancer	0.000169	0.000731	CcSEcCtD
Midazolam—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000169	0.00073	CcSEcCtD
Midazolam—Fatigue—Epirubicin—uterine cancer	0.000169	0.000729	CcSEcCtD
Midazolam—Pain—Epirubicin—uterine cancer	0.000167	0.000723	CcSEcCtD
Midazolam—Constipation—Epirubicin—uterine cancer	0.000167	0.000723	CcSEcCtD
Midazolam—Paraesthesia—Doxorubicin—uterine cancer	0.000162	0.000703	CcSEcCtD
Midazolam—Dyspnoea—Doxorubicin—uterine cancer	0.000161	0.000698	CcSEcCtD
Midazolam—Feeling abnormal—Epirubicin—uterine cancer	0.000161	0.000697	CcSEcCtD
Midazolam—Somnolence—Doxorubicin—uterine cancer	0.000161	0.000696	CcSEcCtD
Midazolam—Dyspepsia—Doxorubicin—uterine cancer	0.000159	0.000689	CcSEcCtD
Midazolam—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000156	0.000676	CcSEcCtD
Midazolam—Fatigue—Doxorubicin—uterine cancer	0.000156	0.000675	CcSEcCtD
Midazolam—Urticaria—Epirubicin—uterine cancer	0.000155	0.000672	CcSEcCtD
Midazolam—Pain—Doxorubicin—uterine cancer	0.000155	0.000669	CcSEcCtD
Midazolam—Constipation—Doxorubicin—uterine cancer	0.000155	0.000669	CcSEcCtD
Midazolam—Feeling abnormal—Doxorubicin—uterine cancer	0.000149	0.000645	CcSEcCtD
Midazolam—Hypersensitivity—Epirubicin—uterine cancer	0.000144	0.000623	CcSEcCtD
Midazolam—Urticaria—Doxorubicin—uterine cancer	0.000144	0.000622	CcSEcCtD
Midazolam—Asthenia—Epirubicin—uterine cancer	0.00014	0.000607	CcSEcCtD
Midazolam—Pruritus—Epirubicin—uterine cancer	0.000138	0.000598	CcSEcCtD
Midazolam—Hypersensitivity—Doxorubicin—uterine cancer	0.000133	0.000577	CcSEcCtD
Midazolam—Asthenia—Doxorubicin—uterine cancer	0.00013	0.000562	CcSEcCtD
Midazolam—Dizziness—Epirubicin—uterine cancer	0.000129	0.000559	CcSEcCtD
Midazolam—Pruritus—Doxorubicin—uterine cancer	0.000128	0.000554	CcSEcCtD
Midazolam—Vomiting—Epirubicin—uterine cancer	0.000124	0.000538	CcSEcCtD
Midazolam—Rash—Epirubicin—uterine cancer	0.000123	0.000533	CcSEcCtD
Midazolam—Dermatitis—Epirubicin—uterine cancer	0.000123	0.000533	CcSEcCtD
Midazolam—Headache—Epirubicin—uterine cancer	0.000122	0.00053	CcSEcCtD
Midazolam—Dizziness—Doxorubicin—uterine cancer	0.00012	0.000518	CcSEcCtD
Midazolam—Nausea—Epirubicin—uterine cancer	0.000116	0.000502	CcSEcCtD
Midazolam—Vomiting—Doxorubicin—uterine cancer	0.000115	0.000498	CcSEcCtD
Midazolam—Rash—Doxorubicin—uterine cancer	0.000114	0.000493	CcSEcCtD
Midazolam—Dermatitis—Doxorubicin—uterine cancer	0.000114	0.000493	CcSEcCtD
Midazolam—Headache—Doxorubicin—uterine cancer	0.000113	0.00049	CcSEcCtD
Midazolam—Nausea—Doxorubicin—uterine cancer	0.000107	0.000465	CcSEcCtD
Midazolam—CYP3A5—Metapathway biotransformation—CYP11A1—uterine cancer	6.03e-05	0.00223	CbGpPWpGaD
Midazolam—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	6.01e-05	0.00222	CbGpPWpGaD
Midazolam—ABCB1—HIF-1-alpha transcription factor network—SMAD3—uterine cancer	5.98e-05	0.00221	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—AKR1C1—uterine cancer	5.88e-05	0.00217	CbGpPWpGaD
Midazolam—CYP2B6—Metapathway biotransformation—AKR1C3—uterine cancer	5.83e-05	0.00215	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	5.78e-05	0.00213	CbGpPWpGaD
Midazolam—CYP2E1—Metapathway biotransformation—AKR1C3—uterine cancer	5.71e-05	0.00211	CbGpPWpGaD
Midazolam—CYP3A5—Metapathway biotransformation—AKR1C3—uterine cancer	5.7e-05	0.0021	CbGpPWpGaD
Midazolam—GABRA1—Transmembrane transport of small molecules—ABCC9—uterine cancer	5.62e-05	0.00207	CbGpPWpGaD
Midazolam—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	5.35e-05	0.00198	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—RRM2—uterine cancer	5.24e-05	0.00193	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—DCN—uterine cancer	5.08e-05	0.00188	CbGpPWpGaD
Midazolam—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	5.04e-05	0.00186	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—AKR1B1—uterine cancer	5.01e-05	0.00185	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—STAR—uterine cancer	5.01e-05	0.00185	CbGpPWpGaD
Midazolam—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	4.86e-05	0.00179	CbGpPWpGaD
Midazolam—SLC22A1—Transmembrane transport of small molecules—ABCC9—uterine cancer	4.81e-05	0.00177	CbGpPWpGaD
Midazolam—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	4.8e-05	0.00177	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—CYP11A1—uterine cancer	4.79e-05	0.00177	CbGpPWpGaD
Midazolam—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	4.69e-05	0.00173	CbGpPWpGaD
Midazolam—CYP2B6—Biological oxidations—CYP19A1—uterine cancer	4.61e-05	0.0017	CbGpPWpGaD
Midazolam—CYP2B6—Metapathway biotransformation—CYP19A1—uterine cancer	4.54e-05	0.00168	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—AKR1C3—uterine cancer	4.52e-05	0.00167	CbGpPWpGaD
Midazolam—CYP2E1—Biological oxidations—CYP19A1—uterine cancer	4.51e-05	0.00166	CbGpPWpGaD
Midazolam—CYP3A5—Biological oxidations—CYP19A1—uterine cancer	4.5e-05	0.00166	CbGpPWpGaD
Midazolam—CYP2E1—Metapathway biotransformation—CYP19A1—uterine cancer	4.45e-05	0.00164	CbGpPWpGaD
Midazolam—CYP3A5—Metapathway biotransformation—CYP19A1—uterine cancer	4.44e-05	0.00164	CbGpPWpGaD
Midazolam—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—uterine cancer	4.21e-05	0.00155	CbGpPWpGaD
Midazolam—GABRR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	4.12e-05	0.00152	CbGpPWpGaD
Midazolam—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	3.94e-05	0.00145	CbGpPWpGaD
Midazolam—GABRQ—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	3.93e-05	0.00145	CbGpPWpGaD
Midazolam—GABRR2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	3.93e-05	0.00145	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—POLD1—uterine cancer	3.93e-05	0.00145	CbGpPWpGaD
Midazolam—GABRB3—BDNF signaling pathway—CTNNB1—uterine cancer	3.9e-05	0.00144	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	3.71e-05	0.00137	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—AKR1C1—uterine cancer	3.68e-05	0.00136	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—CYP19A1—uterine cancer	3.52e-05	0.0013	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—STK11—uterine cancer	3.52e-05	0.0013	CbGpPWpGaD
Midazolam—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	3.44e-05	0.00127	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	3.44e-05	0.00127	CbGpPWpGaD
Midazolam—GABRA1—SIDS Susceptibility Pathways—CXCL8—uterine cancer	3.4e-05	0.00126	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—NDUFB11—uterine cancer	3.35e-05	0.00123	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—SRD5A2—uterine cancer	3.35e-05	0.00123	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.31e-05	0.00122	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—RRM2—uterine cancer	3.28e-05	0.00121	CbGpPWpGaD
Midazolam—GABRG3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	3.24e-05	0.00119	CbGpPWpGaD
Midazolam—GABRB1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	3.19e-05	0.00118	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—DCN—uterine cancer	3.18e-05	0.00117	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.15e-05	0.00116	CbGpPWpGaD
Midazolam—GABRA1—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	3.14e-05	0.00116	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	3.12e-05	0.00115	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—SRD5A2—uterine cancer	3.11e-05	0.00115	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—NDUFB11—uterine cancer	3.11e-05	0.00115	CbGpPWpGaD
Midazolam—GABRR1—Transmission across Chemical Synapses—HRAS—uterine cancer	3.1e-05	0.00114	CbGpPWpGaD
Midazolam—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	3.02e-05	0.00112	CbGpPWpGaD
Midazolam—GABRA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	3.02e-05	0.00111	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—CYP11A1—uterine cancer	3e-05	0.00111	CbGpPWpGaD
Midazolam—GABRA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	2.98e-05	0.0011	CbGpPWpGaD
Midazolam—GABRR2—Transmission across Chemical Synapses—HRAS—uterine cancer	2.96e-05	0.00109	CbGpPWpGaD
Midazolam—GABRQ—Transmission across Chemical Synapses—HRAS—uterine cancer	2.96e-05	0.00109	CbGpPWpGaD
Midazolam—ABCB1—Allograft Rejection—CXCL8—uterine cancer	2.94e-05	0.00109	CbGpPWpGaD
Midazolam—GABRA1—SIDS Susceptibility Pathways—EP300—uterine cancer	2.92e-05	0.00108	CbGpPWpGaD
Midazolam—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	2.91e-05	0.00108	CbGpPWpGaD
Midazolam—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	2.84e-05	0.00105	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—AKR1C3—uterine cancer	2.83e-05	0.00104	CbGpPWpGaD
Midazolam—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	2.82e-05	0.00104	CbGpPWpGaD
Midazolam—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	2.81e-05	0.00104	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	2.8e-05	0.00103	CbGpPWpGaD
Midazolam—GABRA1—SIDS Susceptibility Pathways—VEGFA—uterine cancer	2.76e-05	0.00102	CbGpPWpGaD
Midazolam—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	2.76e-05	0.00102	CbGpPWpGaD
Midazolam—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	2.73e-05	0.00101	CbGpPWpGaD
Midazolam—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	2.65e-05	0.000978	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—MTHFR—uterine cancer	2.65e-05	0.000977	CbGpPWpGaD
Midazolam—GABRA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	2.65e-05	0.000977	CbGpPWpGaD
Midazolam—GABRA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	2.6e-05	0.000959	CbGpPWpGaD
Midazolam—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	2.55e-05	0.000943	CbGpPWpGaD
Midazolam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	2.54e-05	0.000937	CbGpPWpGaD
Midazolam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	2.49e-05	0.00092	CbGpPWpGaD
Midazolam—GABRB3—BDNF signaling pathway—HRAS—uterine cancer	2.48e-05	0.000916	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—SRD5A2—uterine cancer	2.47e-05	0.000913	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—NDUFB11—uterine cancer	2.47e-05	0.000913	CbGpPWpGaD
Midazolam—GABRG3—Transmission across Chemical Synapses—HRAS—uterine cancer	2.43e-05	0.000898	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—SRD5A2—uterine cancer	2.42e-05	0.000895	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—NDUFB11—uterine cancer	2.42e-05	0.000895	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—STAR—uterine cancer	2.42e-05	0.000893	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—AKR1B1—uterine cancer	2.42e-05	0.000893	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—SRD5A2—uterine cancer	2.42e-05	0.000893	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—NDUFB11—uterine cancer	2.42e-05	0.000893	CbGpPWpGaD
Midazolam—GABRB1—Transmission across Chemical Synapses—HRAS—uterine cancer	2.4e-05	0.000885	CbGpPWpGaD
Midazolam—ABCB1—Allograft Rejection—VEGFA—uterine cancer	2.39e-05	0.000882	CbGpPWpGaD
Midazolam—GABRR1—Neuronal System—HRAS—uterine cancer	2.37e-05	0.000876	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.33e-05	0.000861	CbGpPWpGaD
Midazolam—GABRA6—Transmission across Chemical Synapses—HRAS—uterine cancer	2.27e-05	0.000837	CbGpPWpGaD
Midazolam—GABRR2—Neuronal System—HRAS—uterine cancer	2.26e-05	0.000836	CbGpPWpGaD
Midazolam—GABRQ—Neuronal System—HRAS—uterine cancer	2.26e-05	0.000836	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—AKR1B1—uterine cancer	2.25e-05	0.000831	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—STAR—uterine cancer	2.25e-05	0.000831	CbGpPWpGaD
Midazolam—GABRA4—Transmission across Chemical Synapses—HRAS—uterine cancer	2.24e-05	0.000827	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—STK11—uterine cancer	2.2e-05	0.000814	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—CYP19A1—uterine cancer	2.2e-05	0.000814	CbGpPWpGaD
Midazolam—GABRB3—BDNF signaling pathway—AKT1—uterine cancer	2.19e-05	0.000809	CbGpPWpGaD
Midazolam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	2.18e-05	0.000804	CbGpPWpGaD
Midazolam—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	2.09e-05	0.000772	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	2.09e-05	0.00077	CbGpPWpGaD
Midazolam—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	2.06e-05	0.000762	CbGpPWpGaD
Midazolam—GABRB2—Transmission across Chemical Synapses—HRAS—uterine cancer	2.05e-05	0.000756	CbGpPWpGaD
Midazolam—GABRA5—Transmission across Chemical Synapses—HRAS—uterine cancer	1.99e-05	0.000735	CbGpPWpGaD
Midazolam—GABRA3—Transmission across Chemical Synapses—HRAS—uterine cancer	1.95e-05	0.000721	CbGpPWpGaD
Midazolam—GABRA2—Transmission across Chemical Synapses—HRAS—uterine cancer	1.92e-05	0.000709	CbGpPWpGaD
Midazolam—GABRB3—Transmission across Chemical Synapses—HRAS—uterine cancer	1.91e-05	0.000704	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—POLD1—uterine cancer	1.9e-05	0.000701	CbGpPWpGaD
Midazolam—GABRG2—Transmission across Chemical Synapses—HRAS—uterine cancer	1.87e-05	0.000692	CbGpPWpGaD
Midazolam—GABRG3—Neuronal System—HRAS—uterine cancer	1.86e-05	0.000688	CbGpPWpGaD
Midazolam—GABRB1—Neuronal System—HRAS—uterine cancer	1.84e-05	0.000678	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—NDUFB11—uterine cancer	1.83e-05	0.000674	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—SRD5A2—uterine cancer	1.83e-05	0.000674	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—STAR—uterine cancer	1.79e-05	0.00066	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—AKR1B1—uterine cancer	1.79e-05	0.00066	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—AKR1C1—uterine cancer	1.78e-05	0.000655	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—POLD1—uterine cancer	1.77e-05	0.000652	CbGpPWpGaD
Midazolam—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	1.76e-05	0.00065	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—AKR1B1—uterine cancer	1.75e-05	0.000647	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—STAR—uterine cancer	1.75e-05	0.000647	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—STAR—uterine cancer	1.75e-05	0.000645	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—AKR1B1—uterine cancer	1.75e-05	0.000645	CbGpPWpGaD
Midazolam—GABRA6—Neuronal System—HRAS—uterine cancer	1.74e-05	0.000641	CbGpPWpGaD
Midazolam—GABRA4—Neuronal System—HRAS—uterine cancer	1.72e-05	0.000633	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—MTHFR—uterine cancer	1.66e-05	0.000611	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—AKR1C1—uterine cancer	1.65e-05	0.00061	CbGpPWpGaD
Midazolam—GABRA1—Transmission across Chemical Synapses—HRAS—uterine cancer	1.64e-05	0.000604	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—RRM2—uterine cancer	1.58e-05	0.000584	CbGpPWpGaD
Midazolam—GABRB2—Neuronal System—HRAS—uterine cancer	1.57e-05	0.000579	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—DCN—uterine cancer	1.54e-05	0.000567	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	1.53e-05	0.000565	CbGpPWpGaD
Midazolam—GABRA5—Neuronal System—HRAS—uterine cancer	1.52e-05	0.000563	CbGpPWpGaD
Midazolam—GABRA3—Neuronal System—HRAS—uterine cancer	1.5e-05	0.000553	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—PTEN—uterine cancer	1.47e-05	0.000544	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—RRM2—uterine cancer	1.47e-05	0.000544	CbGpPWpGaD
Midazolam—GABRA2—Neuronal System—HRAS—uterine cancer	1.47e-05	0.000543	CbGpPWpGaD
Midazolam—GABRB3—Neuronal System—HRAS—uterine cancer	1.46e-05	0.00054	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—CYP11A1—uterine cancer	1.45e-05	0.000534	CbGpPWpGaD
Midazolam—GABRG2—Neuronal System—HRAS—uterine cancer	1.44e-05	0.00053	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—DCN—uterine cancer	1.43e-05	0.000528	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	1.42e-05	0.000523	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—EP300—uterine cancer	1.4e-05	0.000519	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—POLD1—uterine cancer	1.4e-05	0.000518	CbGpPWpGaD
Midazolam—SLC22A1—Transmission across Chemical Synapses—HRAS—uterine cancer	1.4e-05	0.000517	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—POLD1—uterine cancer	1.38e-05	0.000507	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—POLD1—uterine cancer	1.37e-05	0.000506	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—AKR1C3—uterine cancer	1.37e-05	0.000504	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—CYP11A1—uterine cancer	1.35e-05	0.000497	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	1.34e-05	0.000494	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—STAR—uterine cancer	1.32e-05	0.000487	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—AKR1B1—uterine cancer	1.32e-05	0.000487	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—AKR1C1—uterine cancer	1.31e-05	0.000485	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	1.31e-05	0.000482	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—AKR1C1—uterine cancer	1.29e-05	0.000475	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—AKR1C1—uterine cancer	1.28e-05	0.000474	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—AKR1C3—uterine cancer	1.27e-05	0.000469	CbGpPWpGaD
Midazolam—GABRA1—Neuronal System—HRAS—uterine cancer	1.25e-05	0.000463	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	1.25e-05	0.00046	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	1.18e-05	0.000435	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—RRM2—uterine cancer	1.17e-05	0.000432	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—RRM2—uterine cancer	1.15e-05	0.000423	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—RRM2—uterine cancer	1.14e-05	0.000422	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—DCN—uterine cancer	1.14e-05	0.000419	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.12e-05	0.000415	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.12e-05	0.000415	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—DCN—uterine cancer	1.11e-05	0.000411	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—DCN—uterine cancer	1.11e-05	0.00041	CbGpPWpGaD
Midazolam—SLC22A1—Neuronal System—HRAS—uterine cancer	1.07e-05	0.000396	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—CYP11A1—uterine cancer	1.07e-05	0.000395	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—STK11—uterine cancer	1.06e-05	0.000393	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—CYP19A1—uterine cancer	1.06e-05	0.000393	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—CYP11A1—uterine cancer	1.05e-05	0.000387	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—CYP11A1—uterine cancer	1.05e-05	0.000386	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—PIK3CA—uterine cancer	1.04e-05	0.000384	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—POLD1—uterine cancer	1.04e-05	0.000382	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—AKR1C3—uterine cancer	1.01e-05	0.000373	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1e-05	0.00037	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—STK11—uterine cancer	9.91e-06	0.000366	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—CYP19A1—uterine cancer	9.91e-06	0.000366	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—AKR1C3—uterine cancer	9.9e-06	0.000365	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—AKR1C3—uterine cancer	9.88e-06	0.000365	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—AKR1C1—uterine cancer	9.68e-06	0.000357	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—PTEN—uterine cancer	9.22e-06	0.00034	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	9.21e-06	0.00034	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	8.91e-06	0.000329	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—EP300—uterine cancer	8.79e-06	0.000324	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—RRM2—uterine cancer	8.63e-06	0.000319	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—AKT1—uterine cancer	8.49e-06	0.000313	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—DCN—uterine cancer	8.38e-06	0.000309	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—AKR1B1—uterine cancer	8.13e-06	0.0003	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—STAR—uterine cancer	8.13e-06	0.0003	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—MTHFR—uterine cancer	8e-06	0.000295	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—CYP11A1—uterine cancer	7.9e-06	0.000291	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—CYP19A1—uterine cancer	7.88e-06	0.000291	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—STK11—uterine cancer	7.88e-06	0.000291	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—STK11—uterine cancer	7.71e-06	0.000285	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—CYP19A1—uterine cancer	7.71e-06	0.000285	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—STK11—uterine cancer	7.7e-06	0.000284	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—CYP19A1—uterine cancer	7.7e-06	0.000284	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	7.53e-06	0.000278	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—AKR1C3—uterine cancer	7.46e-06	0.000275	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—MTHFR—uterine cancer	7.45e-06	0.000275	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—PIK3CA—uterine cancer	6.5e-06	0.00024	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—POLD1—uterine cancer	6.38e-06	0.000235	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—AKR1C1—uterine cancer	5.97e-06	0.00022	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—MTHFR—uterine cancer	5.92e-06	0.000218	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—STK11—uterine cancer	5.81e-06	0.000214	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—CYP19A1—uterine cancer	5.81e-06	0.000214	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—MTHFR—uterine cancer	5.8e-06	0.000214	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—MTHFR—uterine cancer	5.78e-06	0.000213	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—RRM2—uterine cancer	5.32e-06	0.000196	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—AKT1—uterine cancer	5.31e-06	0.000196	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—DCN—uterine cancer	5.16e-06	0.000191	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—CYP11A1—uterine cancer	4.86e-06	0.00018	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—AKR1C3—uterine cancer	4.59e-06	0.00017	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—PTEN—uterine cancer	4.45e-06	0.000164	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—MTHFR—uterine cancer	4.36e-06	0.000161	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—EP300—uterine cancer	4.25e-06	0.000157	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—PTEN—uterine cancer	4.14e-06	0.000153	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—EP300—uterine cancer	3.95e-06	0.000146	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—STK11—uterine cancer	3.58e-06	0.000132	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—CYP19A1—uterine cancer	3.58e-06	0.000132	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—PTEN—uterine cancer	3.29e-06	0.000122	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—PTEN—uterine cancer	3.22e-06	0.000119	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—PTEN—uterine cancer	3.22e-06	0.000119	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—PIK3CA—uterine cancer	3.14e-06	0.000116	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—EP300—uterine cancer	3.14e-06	0.000116	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—EP300—uterine cancer	3.08e-06	0.000113	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—EP300—uterine cancer	3.07e-06	0.000113	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—PIK3CA—uterine cancer	2.92e-06	0.000108	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—MTHFR—uterine cancer	2.69e-06	9.93e-05	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—AKT1—uterine cancer	2.57e-06	9.47e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—PTEN—uterine cancer	2.43e-06	8.96e-05	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—AKT1—uterine cancer	2.39e-06	8.81e-05	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—PIK3CA—uterine cancer	2.32e-06	8.57e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—EP300—uterine cancer	2.32e-06	8.55e-05	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—PIK3CA—uterine cancer	2.27e-06	8.4e-05	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—PIK3CA—uterine cancer	2.27e-06	8.38e-05	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—AKT1—uterine cancer	1.9e-06	7e-05	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—AKT1—uterine cancer	1.86e-06	6.86e-05	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—AKT1—uterine cancer	1.85e-06	6.84e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—PIK3CA—uterine cancer	1.71e-06	6.32e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—PTEN—uterine cancer	1.5e-06	5.52e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—EP300—uterine cancer	1.43e-06	5.27e-05	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—AKT1—uterine cancer	1.4e-06	5.16e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.06e-06	3.9e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—AKT1—uterine cancer	8.62e-07	3.18e-05	CbGpPWpGaD
